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MaBACKGROUND Several studies have shown that patients with diabetes mellitus (DM) exhibit an impaired response to
clopidogrel. This may contribute to their increased risk of recurrent atherothrombotic events, despite the use of dual-
antiplatelet therapy. The mechanisms for impaired clopidogrel response in DM patients have not been fully elucidated.
OBJECTIVES The aim of this study was to explore the mechanisms for impaired clopidogrel-mediated platelet
inhibition in patients with DM using a comprehensive methodological approach embracing both pharmacokinetic (PK)
and pharmacodynamic (PD) assessments as well as ex vivo and in vitro investigations.
METHODS Patients (DM, n ¼ 30; non-DM, n ¼ 30) with stable coronary artery disease taking aspirin 81 mg/day and
P2Y12 antagonist naive were enrolled. Blood was collected before and at various times (0.5, 1, 2, 4, 6, and 24 h) after
a 600-mg loading dose of clopidogrel. PD assessments included vasodilator-stimulated phosphoprotein, light trans-
mission aggregometry, and VerifyNow P2Y12 ex vivo, before and after dosing and following in vitro incubation with
escalating concentrations (1, 3, and 10 mM) of clopidogrel’s active metabolite (Clop-AM). Exposure to Clop-AM was
also determined.
RESULTS PD assessments consistently showed that during the overall 24-h study time course, residual platelet reac-
tivity was higher in DM patients compared with non-DM patients. In vitro incubation with Clop-AM revealed altered
functional status of the P2Y12 signaling pathway in DM platelets as measured by vasodilator-stimulated phosphoprotein,
but not with other PD assays. Clop-AM exposure was w40% lower in DM patients than in non-DM patients.
CONCLUSIONS The present study suggests that among DM patients, impaired P2Y12 inhibition mediated by clopidogrel
is largely attributable to attenuation of clopidogrel’s PK proﬁle. This is characterized by lower plasma levels of Clop-AM
over the sampling time course in DM patients compared with non-DM patients and only modestly attributed to altered
functional status of the P2Y12 signaling pathway. (J Am Coll Cardiol 2014;64:1005–14) © 2014 by the American College
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ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome(s)
ADP = adenosine diphosphate
ANCOVA = analysis of
covariance
AUC[0-tlast] = area under the
concentration-time curve
through the sampling time of
the last quantiﬁable
clopidogrel active metabolite
concentration
CAD = coronary artery disease
Clop-AM = clopidogrel’s active
metabolite
Cmax = maximal observed
plasma concentration
CYP = cytochrome P-450
DM = diabetes mellitus
LD = loading dose
LSM = least-square mean
LTA = light transmission
aggregometry
MFI = mean ﬂuorescence
intensity
PD = pharmacodynamic
PGE1 = prostaglandin E1
PK = pharmacokinetic
PRI = platelet reactivity index
PRP = platelet-rich plasma
PRU = P2Y12 reaction units
VASP = vasodilator-stimulated
phosphoprotein
VASP-P = vasodilator-
stimulated phosphoprotein
phosphorylation
VN = VerifyNow
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1006D ual-antiplatelet therapy with as-pirin and an antagonist of theP2Y12 receptor is the cornerstone
of treatment in patients with acute coronary
syndrome (ACS) and in those undergoing
percutaneous coronary intervention (1–3).
Despite the development of newer antiplate-
let agents with more predictable pharmaco-
dynamic (PD) response, clopidogrel is still
the most broadly used P2Y12 receptor antago-
nist (4). However, clopidogrel is character-
ized by a high interindividual variability in
PD effects, and 5% to 44% of treated patients
exhibit impaired responses (5,6). Impor-
tantly, inadequate clopidogrel-induced anti-
platelet effect is associated with an
increased risk of recurrent ischemic events,
including stent thrombosis (5–9). Multiple
factors can contribute to variations in indi-
vidual responses to clopidogrel (5,6,10,11).
Among these, PD investigations from our
group and others have shown that patients
with diabetes mellitus (DM) have impaired
clopidogrel-mediated antiplatelet effects
and higher rates of poor responsiveness
than non-DM patients (12–16). This may
contribute to the enhanced atherothrombotic
risk that characterizes DM patients despite
antiplatelet therapy (17).SEE PAGE 1015The mechanisms of impaired response to
clopidogrel in DM patients remain to be fully
elucidated. A post-hoc subgroup analysis
suggested that the reduced ex vivo PD effects
of clopidogrel among DM patients are sec-
ondary to a less favorable pharmacokinetic(PK) proﬁle (18). In particular, DM patients have
reduced plasma levels of clopidogrel’s active metab-
olite (Clop-AM) compared with those of non-DM pa-
tients (18). An in vitro pilot study suggested that
platelets from DM patients are characterized by up-
regulation of the P2Y12 signaling pathway, which, in
turn, can reduce the PD effects of clopidogrel
(19). Prospective studies speciﬁcally designed to
provide mechanistic insights of impaired clopidogrel
response in DM are lacking. The aim of this pro-
spective study was to explore the underlying mech-
anisms of impaired clopidogrel-mediated platelet
inhibition in DM patients using a comprehensive
methodological approach, embracing both PK and PD
assessments as well as ex vivo and in vitro
investigations.METHODS
PATIENT POPULATION. A total of 60 patients (30 DM
and 30 non-DM) with coronary artery disease (CAD)
taking low-dose aspirin were prospectively recruited.
Patients were screened at the outpatient clinic of the
Division of Cardiology–University of Florida College
of Medicine Jacksonville. Patients were considered
eligible for the study if they met all of the following
inclusion criteria: between 18 and 80 years of age, had
angiographically documented CAD, on treatment
with low-dose aspirin (81 mg/day) for at least 30 days
as part of standard of care, and treatment naive
for P2Y12 antagonism (ticlopidine, clopidogrel, pra-
sugrel, or ticagrelor) for at least 30 days. Patients
were stratiﬁed according to DM status, deﬁned ac-
cording to World Health Organization criteria. All
subjects with DM needed to be on treatment with oral
hypoglycemic agents and/or insulin for at least 2
months without any changes in their regimen (20).
Exclusion criteria were any of the following: use
of any antiplatelet therapy other than aspirin in
the past 30 days, use of parenteral or oral anti-
coagulation in the past 30 days, active bleeding,
hemodynamic instability, any clinical indication to
be on a P2Y12 receptor antagonist, hemoglobin A1c
>12%, use of any drug interfering with cytochrome
P-450 (CYP) metabolism (ﬂuconazole, ketoconazole,
voriconazole, etravirine, felbamate, ﬂuoxetine, ﬂu-
voxamine, omeprazole, esomeprazole, lansoprazole,
rabeprazole), cerebrovascular accident in the past 3
months, any active malignancy, platelet count <100 
106/ml, hemoglobin <10 g/dl, creatinine >2.5 mg/dl,
liver disease (bilirubin levels >2 mg/dl), or pregnant
and lactating females. The study complied with the
Declaration of Helsinki, was approved by the Insti-
tutional Review Board of the University of Florida
College of Medicine–Jacksonville, and all patients
gave their written informed consent.
STUDY DESIGN. This was a prospective study in
which ex vivo and in vitro experiments were con-
ducted. Blood samples for analysis were collected by
the antecubital vein in anticoagulated tubes using a
19-gauge needle. The ﬁrst 2 ml of blood sampled was
discarded to avoid spontaneous platelet activation. In
the ex vivo experimental component of our study,
eligible patients were administered a 600-mg loading
dose (LD) of clopidogrel; blood samples for PK and PD
assessments were collected at a total of 7 time points:
baseline (before LD administration) and 30 min, 1 h,
2 h, 4 h, 6 h, and 24 h after LD. In the in vitro
experimental design of our study, blood samples
collected at baseline only (before LD administration)
PD and PK analysisClopidogrel600 mg
Patients with CAD on
aspirin 81 mg/day
PD analysis
In vitro escalating
concentrations of Clop-AM
30’ 1h 2h 4h 6h 24h
PD and PK analysisClopidogrel600 mg
Baseline
(time 0)
DM
Non-DM
FIGURE 1 Study Design
CAD ¼ coronary artery disease; Clop-AM ¼ clopidogrel active metabolite; DM ¼ diabetes
mellitus; PD ¼ pharmacodynamic; PK ¼ pharmacokinetic.
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1007were used; PD testing was performed before and after
incubation (for 30 min at 37C) with escalating con-
centrations of Clop-AM (1, 3, and 10 mM). Daiichi
Sankyo Co., Ltd. (Tokyo, Japan) provided Clop-AM. A
ﬂow diagram of the study design is presented in
Figure 1.
PD ASSESSMENTS. Three different PD assays were
used for both the ex vivo and in vitro experimental
designs, as described below.
Va sod i l a t o r - s t imu l a t ed pho sphop ro t e i n . The
platelet reactivity index (PRI) was determined using
standard protocols for the vasodilator-stimulated
phosphoprotein (VASP) assay (21–23). Brieﬂy, VASP
phosphorylation (VASP-P) was measured by quanti-
tative ﬂow cytometry using commercially available
labeled monoclonal antibodies (Biocytex Inc., Mar-
seille, France). The mean ﬂuorescence intensities
(MFIs) of VASP-P levels were measured after chal-
lenge with prostaglandin E1 (PGE1) and PGE1 þ aden-
osine diphosphate (ADP). PGE1 increases VASP-P
levels through stimulation of adenylate cyclase; ADP
binding to purinergic receptors leads to inhibition of
adenylate cyclase. Thus, the addition of ADP to
PGE1-stimulated platelets reduces the levels of PGE1-
induced VASP-P. The PRI was calculated as follows:
[(MFI PGE1)  (MFI PGE1 þ ADP)/(MFI PGE1)] $ 100%. A
reduced PRI indicates greater inhibition of the P2Y12
signaling pathway (24).
L ight transmiss ion aggregometry . Light trans-
mission aggregometry (LTA) was performed accord-
ing to standard protocols as previously described
(21–23). Brieﬂy, blood was collected in sodium cit-
rate (3.8%) tubes. Platelet aggregation was then
assessed by the turbidimetric method in a 2-channel
aggregometer (Chrono-Log 490 Model, Chrono-Log
Corp., Havertown, Pennsylvania) using platelet-rich
plasma (PRP). Platelet agonists included 5 and
20 mM ADP. PRP was obtained as a supernatant after
centrifugation of citrated blood at 1,000 rpm for
10 min and was kept at 37C before use. Platelet-poor
plasma was obtained by a second centrifugation at
2,800 rpm for 10 min. For each measurement, light
transmission was adjusted to 0% with PRP and to
100% with platelet-poor plasma. Curves were recor-
ded for 6 min after ADP stimuli, and the level of
platelet aggregation at 5 min was recorded, being
more reﬂective of P2Y12-mediated signaling (25).
Ver i fyNow P2Y12 assay . We used the VerifyNow
(VN) system (Accumetrics, San Diego, California), a
turbidimetric-based optical detection system that
measures platelet-induced aggregation as increased
light transmittance according to the manufacturer’s
instructions, as described (22,23). The VN system is amicrobead agglutination assay with reagents speciﬁc
for the pathways of interest. By combining ADP and
PGE1, the VN P2Y12 assay measures platelet reactivity
changes that are relatively speciﬁc for P2Y12 antago-
nists. Optical signal changes are reported in P2Y12
reaction units (PRUs).
PK ASSESSMENTS. A commercial laboratory (Advion
Biosciences, Inc., Ithaca, New York) blinded to
the nature of the samples determined the plasma
concentration of Clop-AM using liquid chromatog-
raphy with tandem mass spectrometry, according to
standard protocols (26). Blood was drawn into stan-
dard ethylenediamine tetraacetic acid tubes. Within
30 s, a derivatizing agent (30-methoxyphenacyl-
bromide) was added to capture and stabilize the
active metabolite. The geometric mean area under
the concentration-time curve through the sampling
time of the last quantiﬁable Clop-AM concentration
(AUC[0-tlast]) was calculated and the maximum
observed plasma concentration (Cmax) of Clop-AM
was recorded.
Sample s ize est imat ion and study endpo ints .
The sample size was determined on the basis of as-
sumptions derived for the ex vivo component of our
experimental design, in particular, the comparison of
PRI values from patients with and without DM at 6 h
after administration of a 600-mg clopidogrel LD.
Assuming a 13% SD and an w10%, dropout rate, we
would be able to detect a 10% difference in PRI with
60 patients (30 DM and 30 non-DM), with 95% power
and a 2-tailed alpha value of 0.05. PRI was chosen
TABLE 1
V
Age, yrs
Male
Obesity, B
Race
Caucasia
African
Hispanic
Other
Hypertens
Dyslipidem
Active sm
Previous M
PAD
Previous P
Previous C
Previous s
LVEF, %
Creatinine
Platelet co
Medicatio
Insulin t
OAD
Aspirin
Beta-blo
ACEIs/A
Statins
CCB
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Values are m
ACEIs ¼
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OAD ¼ oral
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1008because it is the most speciﬁc marker for P2Y12
receptor–mediated signaling (24,27). As part of our
experimental plan, we justiﬁed our study’s sample
size to detect differences in our ex vivo PD experi-
ments with established methods and then evaluated
the other PK and PD study components. There is a
paucity of published data, limiting the ability to
deﬁne a sample size. The endpoints of our study
included PD assessments (24 h overall time course)
measured by VASP-PRI, LTA, and VN-P2Y12 as part of
the ex vivo component of our experimental design;
PK assessments (Clop-AM plasma concentrations,
Cmax and AUC[0-tlast]) as part of the ex vivo component
of our experimental design; and PD assessments as
listed in the preceding text as part of the in vitro
component of our experimental design.
STATISTICAL ANALYSIS. Conformity to the normal
distribution was evaluated for continuous variablesBaseline Characteristics of the Study Population
ariable
DM
(n ¼ 30)
Non-DM
(n ¼ 30) p Value
58.9  8.8 60.5  9.3 0.496
19 (63.3) 21 (70.0) 0.584
MI $30 kg/m2 21 (70.0) 14 (46.7) 0.067
0.786
n 17 (56.7) 18 (60.0)
American 10 (33.3) 9 (30.0)
1 (3.3) 1 (3.3)
2 (6.7) 2 (6.7)
ion 28 (93.3) 26 (86.7) 0.671
ia 27 (93.1) 26 (86.7) 0.671
oking 10 (33.3) 10 (33.3) 1.00
I 16 (53.3) 14 (46.7) 0.606
4 (13.3) 4 (13.3) 1.00
CI 17 (56.7) 15 (50.0) 0.597
ABG 11 (36.7) 11 (36.7) 1.00
troke 6 (20.0) 1 (3.3) 0.103
56.9  12.6 56.3  9.1 0.904
, g/dl 1.04  0.37 0.95  0.34 0.409
unt, 103/ml 211.5  69.7 244.0  56.2 0.076
ns
herapy 12 (40.0) — —
21 (70.0) — —
30 (100) 30 (100) 1.00
ckers 25 (83.3) 24 (80.0) 0.706
RBs 21 (70.0) 22 (73.3) 0.940
23 (76.7) 25 (83.3) 0.905
8 (26.6) 8 (26.6) 1.00
10 (30.0) 13 (43.3) 0.712
ean  SD or n (%).
angiotensin-converting enzyme inhibitors; ARBs ¼ angiotensin receptor blockers;
mass index; CABG ¼ coronary artery bypass surgery; CCB ¼ calcium-channel blockers;
tes mellitus; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction;
antidiabetic drugs; PAD ¼ peripheral artery disease, PCI ¼ percutaneous coronary
.with the Kolmogorov-Smirnov test. For baseline
characteristics, continuous variables are expressed as
mean  SD and categorical variables are expressed
as frequency and percentage. The chi-square or
Fisher exact test (if the expected value in any
cell was <5) was used to compare categorical vari-
ables between 2 groups, whereas the Student t or
Mann-Whitney U test was used to compare contin-
uous variables, where appropriate. An analysis of
covariance (ANCOVA) method with a general linear
model was used to evaluate all between-group
comparisons, using the baseline value of the corre-
sponding platelet function test and obesity (deﬁned
as a body mass index $30 kg/m2) as covariates. A
repeated-measures ANCOVA model, also adjusted
by baseline platelet function value and obesity
status, was used to evaluate the overall difference
between groups. ANCOVA models were performed
for the previously mentioned analyses in line with
other PK/PD studies (28,29); however, due to the
small sample size (because of the PK/PD nature of
the study), the dependent variable was not always
normally distributed in every combination of values
of the covariate and levels of the factor. PD results
are reported as least-square mean (LSM)  SE for
the detailed analysis in the preceding text. A
2-tailed p value <0.05 was considered to indicate a
statistically signiﬁcant difference for all analyses
performed. Statistical analysis was performed using
SPSS version 21.0 software (SPSS Inc., Chicago,
Illinois).RESULTS
PATIENT POPULATION. A total of 72 patients meet-
ing study inclusion criteria were identiﬁed; 12 of
these declined to participate. Thus, a total of 60
patients (DM, n ¼ 30 and non-DM, n ¼ 30) provided
their written informed consent to participate and
completed the study. Baseline characteristics are
summarized in Table 1 and were similar between
groups, except for obesity status, which was numeri-
cally higher in subjects with DM (p ¼ 0.067). HbA1c
levels were 7.45  1.13% in patients with DM.
EX VIVO PD ASSESSMENTS. PRI levels (measured
by VASP) (Figure 2A) after a 600-mg clopidogrel LD
were signiﬁcantly higher in DM subjects compared
with non-DM during the 24 h of crude analysis
(p ¼ 0.001) and after adjusting for baseline PRI
values and obesity status (p ¼ 0.016). Platelet reac-
tivity measured with LTA with ADP 20 mM after
the 600-mg clopidogrel LD was signiﬁcantly higher
in DM subjects than non-DM subjects (p ¼ 0.005 in
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FIGURE 2 Ex Vivo Pharmacodynamic Assessments After
600-mg Loading Dose of Clopidogrel
(A) Platelet reactivity index measured by the vasodilator-
stimulated phosphoprotein assay. (B) Platelet aggregation
measured by light transmission aggregometry after stimulation
with 20 mM adenosine diphosphate (ADP). (C) P2Y12 reaction units
measured by the VerifyNow-P2Y12 assay. Values are expressed as
least-square means. Error bars indicate SE. The p values indicate
the overall differences between groups assessed by repeated-
measures analysis of covariance and adjusted for baseline values
and obesity. DM ¼ diabetes mellitus.
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1009the unadjusted analysis and p ¼ 0.022 after adjust-
ing for baseline platelet reactivity and obesity)
(Figure 2B). LTA with 5 mM ADP showed higher
platelet reactivity in patients with DM (p ¼ 0.032
in the unadjusted analysis and p ¼ 0.080 after
adjusting for baseline platelet reactivity values and
obesity) (data not shown). Parallel ﬁndings were
observed with PRU values measured with VN-P2Y12
during the overall 24 h after the clopidogrel LD in
the crude analysis (p ¼ 0.039 in the unadjusted
analysis and p ¼ 0.056 after adjusting for baseline
PRU and obesity) (Figure 2C).
PK ASSESSMENTS. After the 600-mg clopidogrel LD,
Clop-AM concentrations throughout the 24-h time
course were lower in DM patients compared with
non-DM patients (Figure 3). Overall exposure to
Clop-AM and Cmax was signiﬁcantly reduced in DM
patients (Table 2). In particular, the geometric LSM
AUC[0-tlast] in DM patients was 62.7% of that observed
for non-DMpatients (32.81 ng $h/ml vs. 52.36 ng $h/ml;
adjusted p ¼ 0.02). Accordingly, the geometric LSM
Cmax in patients with DM was 53.0% of that observed
for patients without DM (19.77 ng/ml vs. 37.32 ng/ml;
adjusted p ¼ 0.004).
IN VITRO PD ASSESSMENTS. In vitro incubation of
DM blood samples collected at baseline with esca-
lating concentrations of Clop-AM showed attenuated
P2Y12 inhibition, reﬂected in signiﬁcantly higher PRI
levels measured by VASP than those from patients
without DM, both in the unadjusted analysis (p ¼
0.006) and after adjustment for baseline PRI and
obesity (p ¼ 0.034) (Figure 4A). Furthermore, PRI af-
ter incubation with 1 mM (p ¼ 0.047) of Clop-AM was
signiﬁcantly higher in patients with DM, but did not
reach statistical signiﬁcance with 3 mM (p ¼ 0.254) and
10 mM (p ¼ 0.062) after adjustment for baseline PRI
and obesity.
LTA with 20 mM ADP showed a higher, but
nonsigniﬁcant, platelet aggregation in DM patients
in the global analysis (p ¼ 0.068 in the unadjusted
analysis and p ¼ 0.228 after adjustment for baseline
platelet reactivity and obesity), and at each Clop-AM
concentration, platelet reactivity did not signiﬁ-
cantly differ between groups (Figure 4B). Similar
trends were observed for LTA with 5 mM ADP
(data not shown). PRU values measured with VN-
P2Y12 after in vitro incubation with escalating con-
centrations of Clop-AM were also similar between
patients with and without DM, both in the global
analysis (p ¼ 0.389 in the unadjusted analysis and
p ¼ 0.567 after adjustment for baseline PRU and
obesity) and at each active metabolite concentration
(Figure 4C).DISCUSSION
The results of the present study, which used a
comprehensive methodological approach embracing
PK and PD assessments and ex vivo and in vitro
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FIGURE 3 Pharmacokinetics of Clop-AM After
600-mg Loading Dose
Mean plasma levels of Clop-AM during the 24 h after a 600-mg
loading dose of clopidogrel. Error bars indicate SE. Clop-AM ¼
clopidogrel active metabolite; DM ¼ diabetes mellitus.
TABLE 2 PK Proﬁle of Clopidogrel Active Metabolite in
Diabetic and Nondiabetic Patients
Parameter
DM
Geometric
LS Means
Non-DM
Geometric
LS Means
Ratio of
Geometric
LS Means, % p value
AUC[0-tlast], ng$h/ml 32.81 52.36 62.7 0.02
Cmax, ng/ml 19.77 37.32 53.0 0.004
Geometric least-square (LS) means and p values were calculated on log-
transformed pharmacokinetic (PK) parameters using an analysis of covariance
method with a general linear model and obesity status as a covariate. Geometric LS
means are presented after back-transformation to the original scale.
AUC[0-tlast] ¼ area under the concentration-time curve through the sampling
time of the last quantiﬁable clopidogrel active metabolite concentration;
Cmax ¼ maximal observed plasma concentration; DM ¼ diabetes mellitus.
Angiolillo et al. J A C C V O L . 6 4 , N O . 1 0 , 2 0 1 4
Impaired Response to Clopidogrel in Diabetes S E P T E M B E R 9 , 2 0 1 4 : 1 0 0 5 – 1 4
1010evaluations, conﬁrm that clopidogrel-mediated
platelet P2Y12 receptor blockade responses are
impaired in patients with DM compared with non-DM
patients. In particular, we found that residual
platelet reactivity after treatment with clopidogrel is
higher in patients with DM than in non-DM patients,
as corroborated by multiple PD assays. In vitro incu-
bation with escalating concentrations of Clop-AM
showed that, as measured by VASP, the functional
status of the P2Y12 signaling pathway in platelets
from DM patients is signiﬁcantly inhibited. In
contrast, with other PD assays, only trends toward up-
regulation of the P2Y12 signaling pathway were
observed. Our study shows that Clop-AM exposure
was w40% lower in DM patients than in non-DM
patients. These ﬁndings suggest that overall im-
paired platelet P2Y12 receptor blockade mediated by
clopidogrel may largely be attributable to abnormal-
ities in the Clop-AM PK proﬁle (“drug exposure”) and
only to a much lesser degree to platelet dysfunction
(drug response) (Central Illustration).
Several studies have demonstrated the clinical
beneﬁt associated with platelet P2Y12 receptor inhi-
bition by clopidogrel, particularly in high-risk set-
tings (1–3). However, a signiﬁcant number of patients
continue to experience poor response to clopidogrel
and are at increased risk of adverse outcomes (4–9).
Multiple factors can contribute to these ﬁndings
(5–11). Among these, PD investigations (from our
group and others) have shown that patients with
DM have impaired clopidogrel-induced antiplateleteffects and higher rates of poor responsiveness
compared with non-DM patients (12–16). This may
explain the characteristic enhanced ischemic risk in
DM patients, including high rates of stent thrombosis,
despite clopidogrel treatment (17). The mechanisms
contributing to inadequate clopidogrel-induced anti-
platelet effects in DM patients are likely multifacto-
rial, although some may be speciﬁc to this patient
population, such as differences in plasma levels of
procoagulant factors, oxidative stress, and cellular
function (17,30,31). In particular, platelets from
patients with type 2 DM have lost responsiveness to
insulin, leading to increased P2Y12-mediated sup-
pression of cyclic adenosine monophosphate and
decreased response to P2Y12 inhibitors (32–34). A
previous investigation by our group demonstrated
that DM platelets exposed in vitro to escalating con-
centrations of Clop-AM had persistently higher PRI
levels than non-DM platelets, suggesting that P2Y12-
mediated signaling is dysfunctional in DM patients
(19). Although the present results are consistent with
these previous in vitro ﬁndings with VASP, no sig-
niﬁcant differences were found with LTA and
VN-P2Y12, which showed only numerical increases in
platelet reactivity in DM patients compared with non-
DM patients. These ﬁndings may also be due to the
greater speciﬁcity of VASP-PRI for the P2Y12 signaling
pathway (24,27).
Inadequate clopidogrel-induced platelet inhibition
among DM patients has also been attributed to sup-
pressed Clop-AM circulating levels. Erlinge et al. (18)
conducted a post-hoc analysis of a small DM sub-
group (n ¼ 9) derived from a prospective PK/PD
investigation and showed that DM patients were
overrepresented among poor responders identiﬁed in
a prospective evaluation comparing prasugrel and
clopidogrel and had signiﬁcantly lower Clop-AM
levels. However, this study did not ﬁnd any differ-
ences between DM and non-DM patients in either PD
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FIGURE 4 In Vitro PD Assessments After Incubation With
Escalating Concentrations of Clop-AM
(A) Platelet reactivity index measured by the vasodilator stimu-
lated phosphoprotein assay. (B)Platelet aggregationmeasured by
light transmission aggregometry after stimulation with 20 mM
adenosine diphosphate. (C) P2Y12 reaction units measured by the
VerifyNow-P2Y12 assay. Values are expressed as least-square
means. Error bars indicate SE. The p values indicate the overall
differences between groups assessed by repeated-measures
analysis of covariance and adjusted for baseline values and
obesity. Abbreviations as in Figure 1.
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1011effects after oral administration of clopidogrel or
in vitro PD effects after incubation with a single high
concentration (10 mM) of Clop-AM. Furthermore, only
a trend toward a lower Clop-AM AUC among DM pa-
tients was observed (18). Overall, these ﬁndings were
likely due to the small size of this analysis. Our
investigation expands on this previous post-hoc
analysis with our prospective, comprehensive PK
and PD assessments and ex vivo and in vitro experi-
ments using an array of assays in a larger study
population. We showed that Cmax and the AUC of
Clop-AM were lower in DM patients than in non-DM
patients. We also used a range of Clop-AM concen-
trations for the in vitro tests. Overall, our study
ﬁndings suggest that impaired platelet P2Y12 receptor
blockade following clopidogrel is largely attributed
to abnormalities in clopidogrel’s PK proﬁle and
only in “small” part attributed to platelet dysfunc-
tion. The mechanisms leading to abnormalities in
clopidogrel’s PK proﬁle among patients with DM
are not fully understood and likely imply multiple
contributing factors. Indeed, it is well-known that
DM patients are affected by gastrointestinal and
hepatic abnormalities that can affect drug absorp-
tion and metabolism (35–37). Therefore, factors
leading to abnormalities in clopidogrel’s PK proﬁle
among patients with DM may include: 1) decreased
gastrointestinal absorption of clopidogrel prodrug;
2) increased clopidogrel prodrug hydrolysis to an
inactive carboxylic acid metabolite; 3) reduced
hepatic CYP activity; and 4) increased Clop-AM
hydrolysis.
The need for more effective platelet-inhibiting
strategies is underscored by the ﬁndings of the pres-
ent investigation and the established knowledge that
patients with DM remain at risk of ischemic re-
currences (17). To achieve this goal, several pilot PD
studies have been conducted speciﬁcally in DM
patients (21–23,38). Indeed, among currently avail-
able strategies, use of the novel and more potent
P2Y12 receptor inhibitors prasugrel and ticagrelor are
the most promising. Recently, Alexopoulos et al. (39)
showed that DM patients with ACS undergoing
percutaneous coronary intervention and pretreated
with clopidogrel achieved higher inhibition when
switched to ticagrelor compared to when switched
to prasugrel. Although prasugrel achieves potent
PD effects, largely attributed to its more favorable
PK proﬁle (i.e., ability to generate its active
metabolite) than that of clopidogrel, DM status also
affects plasma levels of prasugrel active metabolite
(18,28). Whether this is a characteristic of
all oral P2Y12 receptor inhibitors or just of thieno-
pyridines remains to be established, as it is unknownwhether DM status modulates plasma levels of
ticagrelor and its CYP3A4-derived metabolite (AR-
C124910XX). Furthermore, it is possible that because
ticagrelor is administered twice daily, which may be
more optimal for patients with high platelet turnover
CENTRAL ILLUSTRATION Mechanism of Impaired Clopidogrel-Induced P2Y12
Receptor Blockade in Patients With DM
Adenosine diphosphate (ADP) (blue squares)–driven platelet activation and aggregation
contribute to atherothrombotic events. Clopidogrel (red dots), after conversion to its
active metabolite (green triangles), antagonizes P2Y12, the platelet ADP receptor. In
diabetes mellitus (DM) patients treated with clopidogrel, impaired platelet P2Y12 blockade
is largely attributed to marked reductions (w40% lower than nondiabetic subjects) in the
pharmacokinetic proﬁle of clopidogrel’s active metabolite (drug exposure) and attributed
to a much lesser degree to altered functional status of the P2Y12 signaling pathway (drug
response).
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consistent levels of platelet inhibition (40). How-
ever, the rate of high platelet reactivity was ex-
tremely low without a signiﬁcant difference between
prasugrel and ticagrelor (39). These ﬁndings may
explain why both prasugrel and ticagrelor were
beneﬁcial in the DM cohorts of the TRITON-TIMI
38 (Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition with
Prasugrel-Thrombolysis In Myocardial Infarction 38)
and PLATO (Platelet Inhibition and Patient Outcomes)
trials, respectively, although prasugrel appeared tohave a greater net clinical beneﬁt in DM patients
(41,42).
STUDY LIMITATIONS. Our study demonstrates that im-
paired clopidogrel-mediated P2Y12 inhibition among
DM patients is mainly caused by lower Clop-AM
exposure. However, we were not able to determine
whether this reﬂects impaired absorption or metab-
olism or both (35–37). Plasma levels of clopidogrel
prodrug would have helped to differentiate between
these possibilities. Nevertheless, this does not affect
the conclusions of our study. Because our investiga-
tion was performed in patients with stable CAD,
these ﬁndings require conﬁrmation in the setting
of DM patients with ACS who are characterized by
a hyperreactive platelet phenotype and are more
susceptible to absorption and metabolism abnor-
malities (43,44). However, in the ACS setting, the
novel P2Y12 receptor antagonists prasugrel and tica-
grelor are now more frequently used, and clopidogrel
remains the standard of care for stable CAD patients,
the target population of the present investigation
(4). Although this is among the most comprehensive
explorations of the mechanisms associated with
differences in clopidogrel response proﬁles between
DM and non-DM platelets, the complex nature of
the experiments limited our study to a relatively
small number of patients. Indeed, the inherent
differences between DM and non-DM patients indi-
cate that additional confounders, others than
those already accounted for in our statistical ad-
justments, may emerge in a larger study. Finally,
we did not genotype for CYP2C19 polymorphisms
associated with differences in PK/PD proﬁles in
our study; thus, we cannot exclude an allelic fre-
quency imbalance between the DM and non-DM
cohorts (10,11).
CONCLUSIONS
Patients with DM exhibit an impaired platelet
inhibitory response to the P2Y12 receptor inhibitor
clopidogrel. The present mechanistic study suggests
that this can largely be attributed to abnormalities in
clopidogrel’s PK proﬁle, characterized by reduced
plasma levels of Clop-AM that lead to reduced PD
effects, and can only be attributed to a much lesser
degree to dysfunctional P2Y12 signaling pathway
status.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Impaired
responsiveness to the P2Y12 receptor inhibitor clopidogrel
contributes to the increased risk of recurrent athero-
thrombotic events in patients with diabetes mellitus.
TRANSLATIONAL OUTLOOK: Development of
methods to enhance the pharmacokinetic proﬁle of
clopidogrel and increase drug exposure in patients with
diabetes mellitus will likely prove more effective than
interventions that alter the P2Y12 signaling pathway in
an effort to improve platelet inhibition in response to
the drug.
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